A5029489505- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
- Urinary and Genital Oncology Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Fibroblast Growth Factor Research
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Hormonal and reproductive studies
- Boron Compounds in Chemistry
- Ovarian cancer diagnosis and treatment
- Rural and Ethnic Education
- Cancer, Hypoxia, and Metabolism
- Healthcare during COVID-19 Pandemic
- Esophageal Cancer Research and Treatment
IPO Porto
2012-2024
Instituto Português de Oncologia Francisco Gentil
2012-2024
Hospital do Divino Espírito Santo
2024
Centro Hospitalar de Lisboa Central
2024
Research Network (United States)
2022
Centro Hospitalar de Vila Nova de Gaia
2011
Hospital de São Marcos
2011
Abstract Background In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper reports pre-specified quality of life (QoL) outcomes for TAGS. Methods Patients were randomized 2:1 to (35 mg/m 2 twice daily on days 1–5 8–12 each 28-day cycle) plus best supportive care (BSC) or BSC. QoL was evaluated at baseline treatment...
Background: Trifluridine/tipiracil (FTD/TPI), an orally administered combination agent approved for patients with refractory metastatic colorectal cancer, demonstrated promising clinical activity in a gastric cancer Japanese Phase II trial. Therefore, we initiated the TAGS study (NCT02500043) to evaluate efficacy and safety of FTD/TPI heavily pretreated (mGC). Methods: This global III enrolled ≥18 years age with: histologically confirmed, non-resectable mGC, including gastro-oesophageal...
4043 Background: The phase 3, randomized, double-blind, placebo-controlled study (TAGS) evaluated the efficacy and safety of FTD/TPI (35 mg/m² given orally twice a day on days 1–5 8–12 28-day cycle) in mGC patients who had previously received≥2 prior regimens for advanced disease demonstrated clinically relevant statistically significant benefit OS PFS with predictable manageable profile. HRQoL data association between QoL time to ECOG status deterioration (2 or more) are reported here....
Prostate cancer (PC) is one of the leading causes death among men worldwide. Brain metastases from PC are very rare, often presenting in advanced stages disease, and associated with a poor prognosis. Treatment complex may involve surgery or radiotherapy. We present case 64-year-old male diagnosed localized prostate adenocarcinoma, initially treated pelvic radiotherapy long-term hormonal treatment. While on this treatment, around year after radical treatment initiation, he developed bilateral...
Abstract #4111 Introduction
 In breast cancer (BC), adjuvant chemotherapy has become a standard therapy, resulting in prolonged survival. This goal might be affected by dose reductions and delays that are not uncommon features.
 The aim of this study was to assess relative intensity (RDI) reduction risk factors define predictive factors.
 Methods
 Data regarding BC patients (pts) under anthracycline based-chemotherapy regimens collected,...
4040 Background: Gastric cancer is the 5th diagnosis and 3rd cause of death worldwide. Metastatic gastric (mGC) has a median survival 11 months. mGC an heterogeneous disease different biologic characteristics may justify differential therapeutic opportunities. Tumors with homologous recombination (HR) deficiency benefit treatment PARP inhibitors or immune checkpoint inhibitors. The purpose this study was to evaluate prevalence prognostic impact altered expression HR proteins as surrogates...
Barra, S.; Providência, R.; Paiva, L.; Gomes, P.; Caetano, F.; Faustino, C.; Leitão Marques, A. Author Information
Barra, S.; Gomes, P.; Paiva, L.; Caetano, F.; Faustino, C.; Providência, R.; Leitão Marques, A. Author Information
Barra, S.; Paiva, L.; Providência, R.; Gomes, P.; Faustino, C.; Caetano, F.; Leitão Marques, A. Author Information
Introduction: High blood pressure (HBP) is a recognized risk factor for cardiovascular diseases. However, recent studies have shown that in chronic heart failure higher levels of systolic BP (within the normal range) are marker better prognosis. In acute (AHF) hypotension well known worse Purpose: Evaluate patients (P) admitted AHF impact previous history HBP on in-hospital mortality and at 30 days, comparing conditions associated with poor prognosis treatment strategies. Population Methods:...